BLU Looming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BELLUS Health Inc. Investors of Class Action and Lead Plaintiff Deadline: May 17, 2021
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Cannabis Investing Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC
Psychedelics Investing ROSEN, A TOP RANKED LAW FIRM, Encourages Champignon Brands Inc. Investors with Losses over $100K to Secure Counsel Before Important June 9 Deadline in Securities Class Action - SHRMF
ROSEN, A TOP RANKED LAW FIRM, Encourages BELLUS Health Inc. Investors with Losses over $100K to Secure Counsel Before Important May 17 Deadline in Securities Class Action - BLU
Psychedelics Investing DEADLINE ALERT for DDD, DOX, SHRMF, FGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain MetastasisÂ
